LB Pharmaceuticals

tenant

drug

Group Cognitive Behavioral Therapy

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

BEHAVIORAL

Pre-approval / investigational in the US

Developed by University of Arizona

1 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

BEHAVIORAL

Indications

Investigational (via trials)

Schizophrenia Schizophrenia Psychotic Disorders Bipolar Disorder With Psychotic Features Schizoaffective Disorder Psychotic Disorder Not Otherwise Specified (NOS)Major Depression With Psychotic Features

Trials

1

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

NCT01570972—Completed

KOLs & investigators

1

Nicholas Breitborde, Ph.D.KOL score 5

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

University of Arizona

company

trial

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

NA

trial

indication

indication

indication

Psychotic Disorders

indication

Bipolar Disorder With Psychotic Features

indication

KOL

Nicholas Breitborde, Ph.D.

KOL score 5

person